Fig. 7.

Flow cytometric analysis of serum antibody binding from devils with anti-DFT1 antibody response. Ablation of surface B2M in CRISPR/Cas9-mediated B2M knockout cells (B2M^−/−) was confirmed using a monoclonal anti-B2M antibody (anti-B2M ab). Sera from six devils (TD1-TD6) with seroconversion (immune) following DFTD infection were tested against wild-type DFT1 (DFT1.WT), IFNG-treated DFT1 (DFT1.WT + IFNG), IFNG-treated B2M knockout DFT1 (DFT1.B2M^−/− + IFNG), BFP-control (DFT1.BFP), DFT1 overexpressing NLRC5 (DFT1.NLRC5) and B2M knockout NLRC5-overexpressing DFT1 (DFT1.NLRC5.B2M^−/−) cells. An immunized devil with induced tumor regression (My) was included as a positive control, meanwhile serum from a healthy devil (TD7) was included as a negative control as represented in the shaded grey area. Ab, antibody; AF488, Alexa Fluor 488